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Membrane fusion by human immunodeficiency virus type 1 (HIV-1) is promoted by the refolding of the viral
envelope glycoprotein into a fusion-active conformation. The structure of the gp41 ectodomain core in its
fusion-active state is a trimer of hairpins in which three antiparallel carboxyl-terminal helices pack into
hydrophobic grooves on the surface of an amino-terminal trimeric coiled coil. In an effort to identify amino acid
residues in these grooves that are critical for gp41 activation, we have used alanine-scanning mutagenesis to
investigate the importance of individual side chains in determining the biophysical properties of the gp41 core
and the membrane fusion activity of the gp120-gp41 complex. Alanine substitutions at Leu-556, Leu-565,
Val-570, Gly-572, and Arg-579 positions severely impaired membrane fusion activity in envelope glycoproteins
that were for the most part normally expressed. Whereas alanine mutations at Leu-565 and Val-570 destabi-
lized the trimer-of-hairpins structure, mutations at Gly-572 and Arg-579 led to the formation of a stable gp41
core. Our results suggest that the Leu-565 and Val-570 residues are important determinants of conserved
packing interactions between the amino- and carboxyl-terminal helices of gp41. We propose that the high
degree of sequence conservation at Gly-572 and Arg-579 may result from selective pressures imposed by
prefusogenic conformations of the HIV-1 envelope glycoprotein. Further analysis of the gp41 activation process
may elucidate targets for antiviral intervention.
Infection by human immunodeficiency virus type 1 (HIV-1)
is initiated by fusion of the viral and cellular membranes to
allow virus entry into the cell. This process is mediated by the
viral envelope glycoprotein through interaction with cellular
receptors. The HIV-1 envelope glycoprotein is synthesized as a
precursor polyprotein, gp160, that is proteolytically processed
to generate two subunits, the surface glycoprotein gp120 and
the transmembrane glycoprotein gp41 (53). These subunits
remain noncovalently associated to form the oligomeric enve-
lope glycoprotein spike on the viral membrane. gp120 is re-
sponsible for the sequential binding of the envelope glycopro-
tein spike to CD4 and a chemokine receptor (typically CCR5
or CXCR4) on the surface of target cells (reviewed in refer-
ences 2 and 75). These events trigger gp41 to undergo confor-
mational changes that are crucial for activation of HIV-1 mem-
brane fusion. By analogy with the pH-induced structural
changes in the hemagglutinin (HA) protein of influenza virus,
the HIV-1 fusion activation process likely involves substantial
conformational changes from a metastable prefusogenic state
to an energetically more stable fusogenic conformation (re-
viewed in references 14 and 64). The control of these structural
rearrangements is thought to be central to HIV-1 entry and to
strategies for intervention.
The structure and mechanism of the gp41 molecule have
been extensively studied. Protein dissection studies demon-
strated that the N- and C-terminal heptad repeat regions of the
gp41 ectodomain associate to form an -helical trimer of an-
tiparallel dimers (50). X-ray crystallographic analysis con-
firmed that this gp41 core is a trimer of hairpins (13, 68, 69).
Three N-terminal helices form a trimeric coiled coil, and three
C-terminal helices pack in the reverse direction into three
hydrophobic grooves on the surface of the coiled coil. Recent
evidence indicates that this helical-hairpin structure corre-
sponds to the fusion-active conformation of gp41 (13, 36, 50,
68, 69). Because the membrane anchor and the fusion peptide
of the gp41 ectodomain are embedded in the viral and target
cell membranes, respectively, the formation of the fusogenic
hairpin structure results in the colocalization of the two mem-
branes and thus overcomes the energy barrier for membrane
fusion (27, 32, 69).
Peptides corresponding to the C-terminal heptad repeat re-
gion, referred to as C peptides, can specifically inhibit viral
entry into target cells at nanomolar concentrations (37, 73).
One such peptide (T-20) is in clinical study and has shown
antiviral activity in humans (42). T-20 binds to gp41 only after
interaction of the envelope glycoprotein complex with the cel-
lular receptors (27, 39, 56) and is thought to act in a dominant-
negative manner by binding to the N-terminal coiled coil of
gp41 during its conformational change to the fusogenic state
(15, 50, 72). Considerations of the efficiency of C peptide
competition with its cognate sequence suggest a relatively long-
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lived prehairpin intermediate (14, 27, 39, 56). Intermediate
states of the gp41 molecule may serve as a target for the
development of small-molecule HIV-1 inhibitors (22, 25).
Considerable evidence now implies that packing interactions
between the central coiled-coil trimer and the C-terminal helix
are important determinants of HIV-1 entry and its inhibition
(35, 54, 60, 63). For example, the replacement of a conserved
glutamine (Gln-652), buried in this helical interface, by the
hydrophobic residue leucine increases HIV-1 infectivity and
underlies an enhancement in the antiviral activity of C peptides
(8, 63). Biophysical and structural characterization directly
demonstrates that this substitution strengthens the interhelix
interaction in the fusogenic hairpin structure by providing ad-
ditional hydrophobic packing forces (63). Taken together,
these results have been interpreted to indicate that the recep-
tor-triggered conformational changes of the HIV-1 envelope
glycoprotein are thermodynamically controlled and that the
process of membrane apposition and lipid bilayer fusion is
driven by the currency of energy released from the formation
of the fusogenic gp41 core (33, 49, 51, 63, 69).
Therefore, it is of fundamental importance to understand
the structural and mechanistic basis for the helical interactions
in this core. We show here, using alanine-scanning mutagene-
sis, that amino acids Leu-556, Leu-565, Val-570, Gly-572, and
Arg-579 at e and g positions of the N34 coiled coil are essential
for envelope glycoprotein function. Whereas Leu-565 and Val-
570 contribute to the conserved packing interactions between
the N- and C-terminal helices of gp41, Gly-572 and Arg-579
appear to be critical for prefusogenic conformations of the
HIV-1 envelope glycoprotein complex.
MATERIALS AND METHODS
Plasmid construction and mutagenesis. High-fidelity XL PCR (rTth and Vent
DNA polymerases; PE Applied Biosystems) and oligonucleotide primers envA
and envN (29) were used to adapt the HIV-1 HXB2 rev and env genes from the
plasmid pIIIenv 3-1 (65). Expression of the HXB2 envelope glycoprotein was
within the context of the eukaryotic expression vector pCR-Uni 3.1 (Invitrogen)
(45). Alanine mutations were introduced into the HXB2 envelope glycoprotein
and the N34(L6)C28 peptide (51) using QuikChange mutagenesis (Stratagene,
La Jolla, Calif.) and single-stranded mutagenesis (44), respectively. Mutations
were verified by DNA sequencing.
Envelope glycoprotein expression. Simian COS-7 cells were used for transient
expression of the envelope glycoprotein (75). Typically, 3 g of the HIV-1 env
expression plasmid and 9 l of FuGENE-6 reagent (Roche Molecular Biochemi-
cals) were used, according to the manufacturer’s instructions, to transfect 4  105
to 8  105 cells in a 6-cm culture dish. Cultures were washed 18 h later with
physiological buffered saline (PBS) and refed with Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum. Transfection efficiencies were determined
in microcultures from the transfected cell cultures. These microcultures were
fixed with 20°C methanol-acetone (1:1) and stained using biotinylated anti-
HIV immunoglobulin (HIVIG) from infected persons, NeutrAvidin-horseradish
peroxidase (HRP) (Pierce Chemical Corp., Rockford, Ill.), and diaminobenzi-
dine.
Western blot analysis. Two days after transfection, cell culture supernatants
were harvested and filtered. gp120 shed from expressing cells was immunopre-
cipitated using HIVIG and protein A-Sepharose (Sigma). Cell monolayers were
surface biotinylated using EZ-Link NHS-LC-biotin (Pierce Chemical) as previ-
ously described (48, 76). Cells were then lysed on ice in 50 mM Tris-HCl (pH
7.5)–150 mM NaCl–1% Triton X-100 containing 1 g ml1 each of aprotinin,
leupeptin, and pepstatin. Biotinylated surface proteins were isolated by using
NeutrAvidin-agarose (Pierce Chemical). Envelope glycoprotein was detected by
Western blot analysis using the gp120-specific monoclonal antibody (MAb)
Chessie B13 (kindly provided by George Lewis [1]). Western blots were visual-
ized by chemifluorescence using ECL-Plus (Amersham Pharmacia Biotech) and
quantitated by fluorescence imaging using a Fuji FLA3000G instrument.
Deglycosylation of cell surface Env. Biotinylated envelope glycoprotein was
isolated from the cell surface using NeutrAvidin-agarose and was deglycosylated
using protein N-glycanase F (New England Biolabs, Beverly, Mass.). The result-
ing polypeptides were analyzed by Western blot using MAb Chessie 12 (kindly
provided by George Lewis [1]). gp160 from a cleavage-defective envelope gly-
coprotein mutant (26) and soluble gp120 from a truncated envelope glycoprotein
construct were deglycosylated and used as size markers.
Pulse-chase analysis. COS-7 cells expressing envelope glycoprotein were
pulse-labeled for 30 min in replicate six-well cluster dishes using 100 Ci each of
[35S]cysteine and [35S]methionine in 1 ml of cysteine- and methionine-free me-
dium. Cultures were then washed and grown in cysteine- and methionine-con-
taining medium for the indicated times. gp120 was isolated from cell culture
supernatants by immunoprecipitation. Proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and visualized by phosphorimaging.
Cell-cell fusion assay. The ability of the wild-type and mutant envelope gly-
coproteins to mediate cell-cell fusion was determined by coculturing envelope
glycoprotein-expressing COS-7 cells with U87 cells expressing CD4 and CXCR4
coreceptor (31, 45, 49). Transfected COS-7 cells were resuspended using PBS
with 0.5 mM EDTA, and 5  103 cells were added to 96-well microcultures
containing 5  103 U87-CD4-CXCR4 cells. In order to assess the rate and extent
of syncytium formation, cocultures were fixed and immunochemically stained
after 6 and 24 h. The number of envelope glycoprotein-expressing cells involved
in syncytium formation and the number of nuclei contained within each syncy-
tium were determined microscopically.
Peptide production. Mutant N34(L6)C28 peptides were expressed in Esche-
richia coli BL21(DE3)/pLysS using the T7 expression system (67). Cells, freshly
transformed with an appropriate plasmid, were grown to late log phase. Protein
expression was induced by addition of 0.5 mM isopropylthio--D-galactoside.
After another 3 h of growth at 37°C, the bacteria were harvested by centrifuga-
tion, and the cells were lysed by glacial acetic acid as described previously (52).
Proteins were purified from the soluble fraction to homogeneity by reverse-phase
high-pressure liquid chromatography (Waters) with a Vydac C18 preparative
column using a water-acetonitrile gradient in the presence of 0.1% (vol/vol)
trifluoroacetic acid.
CD spectroscopy. Circular dichroism (CD) spectra were acquired on an AVIV
62DS CD spectrometer with a thermoelectric sample temperature controller.
Samples for wavelength spectra were 10 M peptide in 50 mM sodium phos-
phate (pH 7.0) and 150 mM NaCl. The cuvette was 0.1 cm in path length. The
wavelength dependence of molar ellipticity, [], was monitored at 4°C as the
average of five scans, using a 5-s integration time at 1.0-nm wavelength incre-
ments. Spectra were baseline corrected against the value for the cuvette with
buffer alone. Fractional helix content was calculated from the CD signal by
dividing the mean residue ellipticity at 222 nm by the value expected for 100%
helix formation by helices of comparable size (33,000° cm2 dmol1) (17).
Thermal stability was determined in the same buffer by measuring []222 as a
function of temperature. A 1.0-cm path length cell was used with continuous
stirring. Thermal melts were monitored in 2°C intervals with a 2-min equilibra-
tion at the desired temperature and an integration time of 30 s. The midpoint of
the thermal unfolding transition (Tm) was determined from the maximum of the
first derivative, with respect to the reciprocal of the temperature, of the []222
values (7). The error in estimation of Tm is 1°C. Protein concentrations were
determined by measuring absorbance at 280 nm in 6 M guanidinium chloride (23).
Sedimentation equilibrium. Sedimentation equilibrium measurements were
performed on a Beckman XL-A Optima analytical ultracentrifuge, using an
An-Ti rotor and six-sectored equilibrium centrifugation centerpieces. Protein
samples were dialyzed overnight against 50 mM sodium phosphate (pH 7.0)–150
mM NaCl, loaded at initial concentrations of 10, 30, and 100 M, and analyzed
at rotor speeds of 20 and 23 krpm at 20°C. Data were acquired at two wave-
lengths per rotor speed and processed simultaneously with a nonlinear least-
squares fitting routine (38). Solvent density and protein partial specific volume
were calculated according to solvent and protein composition, respectively (47).
Molecular weights were all within 10% of those calculated for an ideal trimer,
with no systematic deviation of the residuals.
Crystallization, data collection, and structure determination. The G572A and
R579A peptides were crystallized by hanging-drop vapor diffusion at room tem-
perature. Initial crystallization conditions were screened by using sparse matrix
crystallization kits (Crystal Screen I and II; Hampton Research, Riverside, Calif.)
and then optimized. Rhombohedral crystals of G572A were grown from 10 mg
ml1 of peptide, 0.1 M sodium acetate (pH 5.2), 0.2 M ammonium sulfate, and
10% polyethylene glycol 4000. Rhombohedral crystals of R579A peptide were
obtained from 20 mg ml1 of peptide, 0.1 M sodium acetate (pH 4.5), 0.2 M
ammonium sulfate, and 29% polyethylene glycol methyl ether 2000. Crystals
were transferred to a cryoprotectant solution containing 15% (vol/vol) glycerol in
VOL. 75, 2001 ALANINE-SCANNING MUTAGENESIS OF gp41 HELICAL INTERFACE 11147
the corresponding mother liquor and frozen in liquid nitrogen for data collec-
tion. Diffraction data on the G572A peptide trimer were collected at 95 K using
an R-axis IV image plate detector mounted on a Rigaku RU200 rotating anode
X-ray generator at the X-ray Crystallography Facility at the Weill Medical
College of Cornell University. Data on the R579A peptide trimer were collected
at 95 K using a Quantum-4 charge-coupled device-based detector at the X12B
beamline of the National Synchrotron Light Source. Diffraction intensities were
integrated by using Denzo and Scalepack software (59) and reduced to structural
factors with the program Truncate from the CCP4 program suite (10).
The structures of the G572A and R579A peptides were determined by mo-
lecular replacement with the program AMoRe (57) using the N34(L6)C28 trimer
(Protein Data Bank [PDB] file name 1SZT) as a search model. The initial models
were built by using conventional (2Fo  Fc)Fcalc and (Fo  Fc)Fcalc maps at 3.0
Å. Overall anisotropic B-factor and bulk solvent corrections were applied. Many
cycles of torsional angle simulated annealing and grouped B-factor refinement
(4) were followed by extensive rebuilding. The models were rebuilt to reflect the
sequences of the G572A and R579A peptides by using the (2Fo  Fc)Fcalc and
(Fo  Fc)Fcalc maps with the program O (40). The structures were refined by
using positional and B-factor refinements (4). Crystallographic refinement of the
structures was done with the program CNS 1.0 (5). Model geometry was analyzed
by Procheck (46), with all residues occupying most-preferred regions of the
Ramanchandran space. Ser-546, Gly-547, Asn-651, Gln-652, Gln-653, Glu-654,
and Lys-655 of the G572A and R579A peptides were left out of the model
because of the absence of interpretable electron density for these atoms. Atomic
coordinates for G572A peptide (PDB file name 1I5Y) and R579A peptide (PDB
file name 1I5X) have been deposited in the PDB.
RESULTS
In the trimer-of-hairpins structure, residues at positions a
and d of the C28 helix pack against residues at the e and g
positions of the N34 coiled-coil trimer in an antiparallel ori-
entation (Fig. 1). Sequence comparisons among HIV-1 isolates
and between HIV-1 and simian immunodeficiency virus (SIV)
show that the residues at these contact positions are highly
conserved (43). This high degree of sequence conservation
may result from selective pressure to maintain interhelical
packing interactions and, hence, the structural integrity of the
trimer of hairpins. To directly test this hypothesis, we changed
the individual e and g residues of N34 to alanine in both the
recombinant N34(L6)C28 peptide model and the intact enve-
lope glycoprotein (Fig. 1C). Alanine-scanning mutagenesis was
chosen because alanine, albeit a good helix-inducing residue,
has a relatively low hydrophobicity and contributes little to
protein-protein interactions (19). We reasoned that alanine
replacements were likely to alter the stability of the trimer-of-
hairpins structure but not to disrupt its folding per se. In this
analysis, the biophysical properties of mutant N34(L6)C28
peptides were compared with the biological phenotypes of
mutant envelope glycoproteins.
Expression of mutant envelope glycoproteins. Alanine mu-
tant envelope glycoproteins were expressed by transient trans-
fection in COS-7 cells. As determined by Western blot analysis
of cell surface-biotinylated proteins, all mutant envelope gly-
coproteins were expressed and transported to the cell surface
with efficiencies comparable to that of the wild-type glycopro-
FIG. 1. Core structure of the HIV-1 gp41 envelope glycoprotein. (A) Schematic representation of gp41. The important functional features of
the gp41 ectodomain and the amino acid sequences of the N34 and C28 segments are shown. Amino acids mutated to alanine in this study are
indicated by dots above the sequence. The naturally occurring alanine at position 558 was not altered. The disulfide bond and four potential
N-glycosylation sites are depicted. The residues are numbered according to their position in gp160. The recombinant N34(L6)C28 peptide model
consists of N34 and C28 plus a linker of six hydrophilic residues. (B) Cross-section of helix packing in the gp41 core. Residues at the a and d
positions of the N helices form the hydrophobic interface of the trimeric coiled coil, and residues at the a and d positions of the C helices pack
in an antiparallel orientation against residues at the e and g positions of adjacent N helices. (C) Helical wheel projection of the heptad repeat
sequence of the N34 peptide. The view is from the NH2 terminus.
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tein (Fig. 2A). The predominant species of envelope glycop-
rotein on the cell surface was gp160. The incomplete cleavage
of the gp160 precursor is likely due to saturation of the cellular
furin-like proteases that are responsible for envelope glyco-
protein processing (3). gp120 represented 	10 to 20% of the
envelope glycoprotein on the cell surface. This was observed in
the wild-type and in all alanine mutant proteins except G572A.
In order to quantitate the relative amounts of cell surface
gp120 among the mutants, we deglycosylated the cell surface
glycoproteins to generate discrete polypeptides (Fig. 2B).
Steady-state levels of gp120 in the alanine mutants V549A,
Q551A, Q563A, L565A, V570A, and Q577A were similar to
that in the wild-type glycoprotein. We conclude that alanine
substitutions at Val-549, Gln-551, Gln-563, Leu-565, Val-570,
and Gln-577 did not affect envelope glycoprotein transport to
the cell surface, gp160 cleavage, or gp120-gp41 association. By
contrast, the G572A mutant glycoprotein exhibited a 10-fold
reduction in the relative amount of cell surface gp120. Lesser
reductions were also noted in the L556A and R579A mutants
(two- and fourfold, respectively).
To examine whether the marked decrease in the steady-state
level of gp120 in the G572A mutant was due to a reduction in
the efficiency of gp160 cleavage, we analyzed the rate of ap-
pearance of gp120 in the cell culture medium. Given the high
rate of spontaneous gp120 shedding from the envelope glyco-
protein complex (55), we reasoned that this assay would pro-
vide a sensitive measure for gp160 cleavage efficiency. If pro-
teolytic cleavage were reduced by the mutation, the amount of
shed gp120 would likewise be reduced. Figure 3 shows the time
course from a pulse-chase labeling experiment. The rate
and/or extent of gp120 shedding in G572A was not decreased
relative to that of the wild-type glycoprotein. We conclude that
the reduction in gp120 accumulation in G572A is not due to a
defect in proteolytic cleavage. By extension, the reduction in
the steady-state level of gp120 in the G572A mutant may be
caused by an increase in gp120 shedding; the Gly-572-to-Ala
mutation may affect the stability of the gp120-gp41 association.
In the pulse-chase labeling experiments (Fig. 3), the L556A
and R579A mutants exhibited a slight reduction in the rate
and/or extent of gp120 shedding relative to the wild-type gly-
coprotein. The significance of this finding is unclear, as a sim-
ilar decrease was observed in Q577A, a mutant in which the
gp120 accumulation on the cell surface was unaltered. The
mechanism for the two- to fourfold reduction in the steady-
state levels of gp120 in L556A and R579A remains undefined.
Taken together, our results indicate that the biosynthesis
and expression of the V549A, Q551A, Q563A, L565A, V570A,
and Q577A envelope glycoproteins were unaffected by alanine
substitutions (Table 1). On the other hand, G572A, L556A,
and R579A displayed reduced steady-state levels of gp120 on
the cell surface.
Fusogenic potential of mutant envelope glycoproteins. The
ability of the alanine mutant envelope glycoproteins to mediate
cell-cell fusion was assessed by coculturing transfected COS-7
cells with a fusion partner, U87 cells expressing CD4 and
CXCR4. In this assay, syncytium formation proceeds rapidly,
and the maximum number of syncytia is typically attained by
6 h of coculture. Thereafter, neighboring syncytia begin to
fuse, resulting in a decreased number of syncytia and an in-
creased number of nuclei per syncytium. By these criteria,
V549A, Q551A, Q563A, and Q577A were indistinguishable
FIG. 2. Cell surface expression of mutant envelope glycoproteins.
Mutant and wild-type envelope glycoproteins were transiently ex-
pressed in COS-7 cells, and cell surface proteins were biotinylated
using NHS-LC-biotin. Mutant envelope glycoprotein names are abbre-
viated by the position number. (A) Envelope glycoprotein was immu-
noprecipitated using HIVIG and detected by Western blot analysis
using NeutrAvidin-HRP and ECL-Plus imaging. Representative im-
ages obtained from the analysis of comparably transfected cell cultures
(40 to 60% transfection efficiency) are shown. (B) Biotinylated enve-
lope glycoproteins were deglycosylated and detected by Western blot
analysis using the gp120-specific MAb Chessie 12 (1) and ECL-Plus
imaging. HXB2 gp160 and gp120 were similarly deglycosylated to
provide size markers (p160, 94 kDa; and p120, 55 kDa). Using this
method of analysis, we noted a consistent diminution in the ratio of
gp120 to gp160. Although the basis for this apparent skewing is not
known, the relative amounts of gp120 among the mutants are retained
relative to the analysis of the unmodified glycoproteins. A dark image
is used to emphasize deglycosylated gp120s.
FIG. 3. Pulse-chase analysis of gp120 shedding by mutant envelope
glycoproteins. Cells expressing mutant (L556A, G572A, Q577A, or
R579A) and wild-type envelope glycoproteins were pulse-labeled for
30 min using [35S]cysteine and [35S]methionine. Comparable amounts
of radioactivity were incorporated in envelope glycoproteins by all
cultures (1.2  104 to 2.2  104 phosphostimulated luminescence units
in gp160). Culture supernatants were harvested at 1, 3, 6, and 20 h, and
gp120 was immunoprecipitated using HIVIG. Proteins were resolved
by SDS-polyacrylamide gel electrophoresis, and radioactivity was visu-
alized by phosphorimaging.
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from the wild-type envelope glycoprotein in fusogenic poten-
tial (Fig. 4). In contrast, V570A, G572A, and R579A failed to
produce syncytia within 6 h of coculture, and L556A and
L565A yielded 100-fold fewer syncytia than the wild-type gly-
coprotein. By 20 h of coculture, R579A, L556A, and L565A
were able to generate similar numbers of syncytia as the wild-
type envelope glycoprotein, but these syncytia were small and
similar to those seen at 6 h with the wild-type glycoprotein. The
V570A mutant produced only a few binucleated cells after 20 h
of coculture, and G572A was entirely defective.
In summary, V570A, G572A, R579A, L556A, and L565A
were severely debilitated in their ability to mediate membrane
fusion (Table 1). Because the alanine substitutions in these
mutants did not grossly affect envelope glycoprotein biosynthe-
sis, our results raise the possibility that the alanine mutations
may perturb the interhelical packing interactions in the gp41
core structure, thereby modulating the membrane fusion ac-
tivity of the envelope glycoprotein complex.
Biophysical analysis of mutant N34(L6)C29 peptides. Vari-
ants of the recombinant N34(L6)C28 peptide with single ala-
nine substitutions at the e and g positions of the N34 coiled coil
were produced by bacterial expression and purified by reverse-
phase high-performance liquid chromatography. Sedimenta-
tion equilibrium measurements indicated that each peptide
sedimented as a discrete trimer over a total peptide concen-
tration of 10 to 100 M at neutral pH (Fig. 5A; Table 2). The
helical content and stability of mutant N34(L6)C28 complexes
were quantitated by CD. Each peptide was 
90% helical at
4°C at 10 M peptide (Table 2), and each exhibited a cooper-
ative thermal unfolding transition (Fig. 5B; Table 2). Under
these conditions, the midpoints of the thermal transition (Tm)
for N34(L6)C28 (wild type), V549A, Q551A, L556A, Q563A,
L565A, V570A, G572A, Q577A and R579A were 70, 73, 74,
64, 68, 50, 56, 82, 76, and 72°C, respectively (Fig. 5B; Table 2).
Therefore, alanine mutations at the e and g residues of the N34
helix caused only changes in thermal stability, without signifi-
cantly influencing the overall topology. In general, introduc-
tion of alanine for bulky hydrophobic residues markedly de-
stabilized the trimer-of-hairpins structure; the decrease in
thermal stability, Tm, between the wild-type and mutant pep-
tides was 6, 20, and 14°C for Leu-556, Leu-565, and Val-570,
respectively. On the other hand, the Gly-572-to-Ala substitu-
tion led to appreciable stabilization of the trimer of hairpins,
reinforcing the observation that glycine in -helices is generally
destabilizing (reviewed in reference 41).
These results indicate that the destabilization of the gp41
ectodomain core by alanine mutations at Leu-565 and Val-570
may underlie the fusion-defective phenotype of the mutant
envelope glycoproteins (Tables 1 and 2). In contrast, alanine
mutations at Gly-572 and Arg-579 stabilized the gp41 core
structure but severely impaired membrane fusion activity. This
effect on fusogenicity may reflect the reduced level of mature
gp120 in these mutants. The L556A mutant had an interme-
diate phenotype, where both the thermal stability of the gp41
core and the level of cell surface gp120 in the envelope glyco-
protein complex were slightly reduced. Interestingly, the Gly-
572 residue is involved in the formation of hydrophobic cavities
on the surface of the N34 trimer that are crucial for interhelical
packing interactions (13, 35, 60). The Arg-579 side chain, on
the other hand, does not directly participate in the helical
interactions (13, 68, 69).
Crystal structures of G572A and R579A peptides. The un-
expected observation that alanine mutations at Gly-572 and
Arg-579 disrupt envelope glycoprotein function while main-
taining the thermal stability of the gp41 ectodomain core led us
to examine the atomic detail of the respective trimer-of-dimer
TABLE 1. Expression and fusion activity of mutant
envelope glycoproteins
Glycoprotein Cell surfaceexpressiona
Cell surface
gp120/gp160b
ratio
gp120
sheddingc
Fusion
activityd
Wild type    
V549A    
Q551A    
L556A    
Q563A    
L565A    
V570A    
G572A    
Q577A    
R579A    
a , comparable to wild-type envelope glycoprotein.
b , comparable to wild-type envelope glycoprotein; , 2- to 4-fold
reduction; , 10-fold reduction.
c , comparable to wild-type envelope glycoprotein, as assessed by West-
ern blot analysis and/or by pulse-chase measurements; , slight reduction in
gp120 shedding.
d , comparable to wild-type envelope glycoprotein; , severe (100-
fold) reduction in fusion ability; , complete absence of fusion. Intermediate
levels of impairment were not represented in these mutations.
FIG. 4. Cell-cell fusion activity of mutant envelope glycoproteins.
Cells expressing mutant and wild-type envelope glycoproteins were
cocultured with U87-CD4-CXCR4 cells for either 6 or 24 h. Cultures
were fixed with 20°C methanol-acetone (1:1), and envelope glycop-
rotein-expressing cells were visualized by immunochemical staining.
The number of envelope glycoprotein-expressing cells involved in syn-
cytium formation and the average number of nuclei contained within
each syncytium were determined. Mutant envelope glycoprotein labels
are abbreviated by the position number. The graph indicates the num-
ber of syncytia at 6 and 24 h (gray and black bars, respectively). The
average size of the syncytia (number of nuclei per syncytium at 6 and
24 h) is indicated at the top. na, not applicable. Results depicted are
from one experiment and are representative of relative differences
among mutants. Note that the number of syncytia is biphasic with time
and typically decreases at longer times as syncytia merge.
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structures. The G572A and R579A peptides were crystallized,
and their X-ray structures were determined to 2.1 and 1.8 Å,
respectively, using molecular replacement methods. The crys-
tals of both G572A and R579A belong to the space group R3
and contain the trimer formed around the crystallographic
threefold axis. The electron density maps of G572A and
R579A reveal the positions of all of the amino acid residues
except a few disordered side chains at the helix termini (see
Materials and Methods). Simulated-annealing omit maps were
calculated to confirm the assignment of the side chains. The
structure of the the G572A peptide was refined to a conven-
tional R-factor of 20.6%, with a free R-factor of 23.4% over a
resolution range of 50.0 to 2.1 Å, and the final model consists
of 61 amino acid residues and incorporates 38 water molecules
and a sulfate ion. The structure of the R579A peptide was
refined against 50.0 to 1.8 Å resolution data to yield a conven-
tional R-factor of 17.9%, with a free R-factor of 19.8%, and the
final model includes 61 residues, 83 water molecules, and a
sulfate ion. Table 3 summarizes the data collection and refine-
ment statistics for these two structures.
As expected, the overall folds of G572A and R579A are very
similar to those of the wild-type molecule. In all cases, the
interior N34 coiled coil of three parallel helices, wrapped in a
gradual left-handed superhelix, is surrounded by a sheath of
antiparallel C28 helices (Fig. 6). At the center of the trimer of
hairpins, the N34 three-stranded coiled coil displays typical
FIG. 5. Biophysical characterization of mutant N34(L6)C28 pep-
tides. (A) The L556A (open rhombs), L565A (open circles), and
G572A (open triangles) peptides form three-stranded bundles. Sedi-
mentation equilibrium data (20 krpm) were collected at 20°C at pH 7.0
for L556A (30 M), L565A (100 M), and G572A (10 M). The
natural logarithm of the absorbance at 280, 236, and 230 nm is plotted
against the square of the radial position. For an ideal single-species
system, this plot is linear, with the slope proportional to the molecular
weight of the molecule. (B) Thermal melts monitored by CD at 222 nm
for L556A (open rhombs), L565A (open circles), V570A (solid circles),
G572A (open triangles), and R579A (solid triangles) peptides at 10
M at pH 7.0.
TABLE 2. Alanine mutants of the HIV-1 gp41 ectodomain core
form trimer-of-hairpins structures
Mutant []222 (degrees cm
2
dmol1)
Tm
(°C)
Molecular mass
(kDa)
N34(L6)C28 31,300 70 24.4
V549A 31,100 73 23.9
Q551A 30,800 74 23.7
L556A 30,500 64 23.2
Q563A 31,200 68 24.2
L565A 31,500 50 22.9
V570A 29,900 56 23.3
G572A 31,400 82 23.5
Q577A 31,000 76 23.6
R579A 31,900 72 24.1
TABLE 3. X-ray data collection and refinement statistics
Statistic G572A R579A
Unit cell dimensions
a, b, c (Å) 52.06, 52.06,
59.74
51.25, 51.25,
59.87
, ,  (degrees) 90, 90, 120 90, 90, 120
Space group R3 R3
Data processing
Resolution (Å) 50–2.1 50–1.8
Measured reflections 23,645 40,929
Unique reflections 3,509 5,440
Completeness (%) 99.5 99.6
Rmerge (%)
a 2.9 3.5
Refinement
Resolution (Å) 50–2.1 50–1.8
Reflections in working set 3,153 4,860
Reflections in test set 356 580
Protein nonhydrogen
atoms
486 490
Water molecules 38 83
Sulfate ion 1 1
Rfree (%)
b 23.4 22.2
Rcryst (%)
b 20.6 17.9
Average B-factor (Å) 37.8 19.8
Rms deviations from ideality
Bond lengths (Å) 0.004 0.008
Bond angles (degrees) 0.7 1.0
Torsion angles (degrees) 15.0 14.8
a Rmerge  I  I/I, where I is the intensity of an individual measurement
and I is the average intensity from multiply recorded reflections.
b Rcryst  Fobs  FcalcFobs, where Fobs and Fcalc are observed and calcu-
lated structural factors, respectively. No -cutoff was applied. Rfree is calculated
for a set of reflections that were excluded from refinement.
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acute knobs-into-holes packing, where the a and d side chains
(knobs) fit into the spaces (holes) between four residues on the
neighboring helices (Fig. 7A and B) (18, 30). Residues at the e
and g positions of the N34 helices lie on the outside of the
trimeric coiled coil and form three hydrophobic grooves on the
surface of this coiled coil. The Gly-572 and Arg-579 residues
replaced in G572A and R579A, respectively, are both in g
positions of N34. The root-mean-square (rms) deviations be-
tween all C atoms of the central N34 coiled coil in the wild-
type and mutant molecules are 0.27 Å for G572A and 0.30 Å
for R579A. The C28 helices in G572A and R579A can also be
superimposed upon the wild-type counterpart with rms devia-
tions of 0.40 and 0.35 Å, respectively. Thus, the fusion-defec-
tive Gly-572-to-Ala and Arg-579-to-Ala mutations do not sig-
nificantly alter the trimer-of-hairpins structure.
On the surface of the N34 trimeric coiled coil, there are
three prominent, symmetry-related cavities (	400 Å3) that
each accommodate three hydrophobic residues from the abut-
ting C28 helix: Trp-628, Trp-631, and Ile-635 (13, 68, 69).
These conserved coiled-coil cavities have been shown to be
critical for HIV-1 entry and its inhibition and provide a poten-
tial antiviral drug target (12, 13, 22, 25, 35, 66). The Gly-572
residue, which is involved in forming this cavity, is invariant in
all 251 fully sequenced M group HIV-1 isolates (43). The
substituted Ala-572 side chains point into the triangular inter-
helical space between two N34 helices and a buttressing C28
helix (Fig. 7C). The favorable van der Waals interactions be-
tween the Ala-572 and Trp-631 side chains can strengthen
interhelical packing and stabilize the trimer-of-hairpins struc-
ture, as suggested by the large increase in Tm of G572A relative
to that of N34(L6)C28. In addition, the Gly-572-to-Ala substi-
tution also leads to local structural rearrangements: the side
chains of Trp-628 and Ile-635 deviated substantially. Overall,
the methyl groups of the Ala-572 residues in G572A pack
efficiently into the hydrophobic cavity of N34 and make a good
C28 interaction (Fig. 7C).
The conserved grooves along the N34 coiled-coil surface are
lined with predominantly hydrophobic residues (Fig. 1C). In-
terestingly, the Arg-579 residue at a g position is completely
conserved in 245 of the 251 sequenced HIV-1 strains. Of the
remaining six isolates with different residues at this position,
three possess a conservative lysine substitution (43). In gp41
core crystal structures (13, 68, 69), the Arg-579 side chain is
poorly ordered, as suggested by very high individual atomic B
factors. While electron density for Ala-579 in the R579A pep-
tide is unambiguous, this substituted residue contributes little
to the interhelical packing interactions. It would therefore ap-
pear that the slight stabilization of the trimer-of-hairpins struc-
ture associated with the alanine substitution at Arg-579 reflects
the favorable helix propensity of alanine relative to arginine in
the wild-type molecule.
DISCUSSION
The HIV-1 envelope glycoprotein complex controls the key
process of viral entry. The current model of HIV-1 membrane
fusion implies that, as the trimer of hairpins is assembled, a
ready source of energy can be made available for overcoming
the activation energy needed for lipid bilayer fusion. Because
the native and prehairpin intermediate conformations of gp41
are not known, the basic property of gp41 activation during
HIV-1 membrane fusion is not well understood. Nevertheless,
FIG. 6. Overall views of the mutant G572A and R579A peptide six-helix bundles. (A) Side view. The amino termini of N34 and the carboxyl
termini of C28 are at the top of the figure. Helices of G572A (yellow) and R579A (pink) peptides were used for the superposition. (B) View from
the top, looking down the threefold axis of the trimer of hairpins. Figures were generated with the program Setor (24).
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as has been established for the case of influenza virus HA
protein (6, 9, 74), it is widely believed that the native gp41
structure is substantially different from the fusogenic trimer-
of-hairpins structure. In the simplest model, the N-terminal
heptad repeat region of gp41 exists in an non-coiled-coil con-
formation in the native state but forms a coiled-coil trimer in
the prehairpin intermediate and fusogenic hairpin conforma-
tions (16, 21, 34, 51, 70, 73). The N-terminal heptad repeat
sequence is one of the most highly conserved regions within
the primate immunodeficiency virus envelope glycoproteins
(11, 20, 28). Residues at the a and d positions form a hydro-
phobic interface at the interior of the N-terminal trimeric
coiled coil (62). There is only one nonconservative substitution
at an a position between HIV-1 and SIV (Ile-573 in HIV-1 and
Thr in the corresponding position of SIV). Mutations at this
position affect the folding and stability of the gp41 ectodomain
core and, coordinately, the ability of the mutant envelope gly-
coproteins to mediate membrane fusion (21, 49, 51). Forma-
tion of the N-terminal three-stranded coiled coil appears to
occur as an early event in the gp41 refolding process.
The N-terminal coiled-coil surface contains three hydropho-
bic grooves that are the sites for the C-terminal helix interac-
tions (13, 68, 69). The e and g residues lining these grooves
pack against residues at the a and d positions of the C-terminal
helices. The high sequence conservation at these contact po-
sitions has led to the proposal that interactions between the N-
and C-terminal helices are important for the resolution of the
prehairpin intermediate into the hairpin structure during
membrane fusion (13, 68, 69). Indeed, mutagenesis studies
demonstrate that mutations at these interhelical interface po-
sitions often abolish infectivity and membrane fusion (70, 71).
This proposal is also consistent with a large body of data on the
inhibition of HIV-1 infection and syncytium formation by de-
rivatives of the peptides that make up the gp41 core (12, 35, 49,
FIG. 7. Conserved interhelical interactions in the crystal structures of the G572A and R579A trimers. The final 2Fo  Fc electron density maps
of the G572A and R579A peptides are shown with the refined model superimposed (panels A and B, respectively). Oxygen, nitrogen, and carbon
atoms are colored red, blue, and yellow, respectively. The maps are contoured at 1.0 standard deviation above the average density. Interactions
of the C28 helix with a deep cavity on the surface of the N34 coiled coil of the G572A and R579A peptides are shown (panels C and D,
respectively). The C28 helices, represented as ribbons, are drawn against a surface representation of the N34 coiled coil. The side chains of the
mutated residues are colored green. Figures were generated with the programs Setor (24) and Grasp (58).
VOL. 75, 2001 ALANINE-SCANNING MUTAGENESIS OF gp41 HELICAL INTERFACE 11153
61). In the present study, we have investigated the role of
individual side chains at the nine e and g positions of the N34
coiled coil in conferring structural specificity and conforma-
tional stability to the gp41 core and in determining the fusion
potential of the envelope glycoprotein complex.
Our alanine-scanning mutagenesis results show that the
Leu-556, Leu-565, Val-570, Gly-572, and Arg-579 residues play
a critical role in envelope glycoprotein function, while the
Val-549, Gln-551, Gln-563, and Gln-577 side chains per se are
not essential for this membrane fusion activity. These findings
with regard to L556A, Q563A, V570A, G572A, and Q577A
agree with those reported previously by Weiss and colleagues
(70, 71). Our biophysical analysis reveals that alanine muta-
tions in the fusion-defective L565A and V570A envelope gly-
coproteins destabilize the trimer of hairpins by a Tm shift of
	14 to 20°C. In contrast, the Tms of the four mutant gp41 cores
carrying the fusion-competent alanine substitutions are com-
parable to or even higher than that of the wild-type molecule.
In general, the stability of the trimer-of-hairpins structure
modulates the membrane fusion properties of the gp120-gp41
complex. Interestingly, the fusion-defective Gly-572-to-Ala
and Arg-579-to-Ala mutations lead instead to enhanced stabi-
lization of the gp41 core structure.
The conformational stability of the gp41 core structure is
thought to play a critical role in the refolding of the envelope
glycoprotein into a fusion-active conformation (33, 34, 49, 51).
Although melting temperature has been useful as a qualitative
guide to thermodynamic stability, it appears that the depen-
dence of HIV-1 fusion potential on the stability of the trimer
of hairpins can vary. In contrast to our previous observation
that the Ile-573-to-Thr substitution decreases the thermal sta-
bility of the gp41 core by 25°C relative to the wild-type mole-
cule and has only moderate effects on membrane fusion activ-
ity (49), we show here that a destabilization of the trimer of
hairpins by a Tm shift of 14 to 20°C can markedly reduce the
fusion potential of the envelope glycoprotein. It is possible that
the a position Ile-573-to-Thr mutation affects formation of the
N-terminal coiled coil of gp41 after interaction of the envelope
glycoprotein complex with cellular receptors, while the alanine
mutations at the e and g positions studied here act on the
association of the C-terminal helices with the N-terminal
coiled coil during the transition from the prehairpin interme-
diate to the trimer-of-hairpins structure.
The crystal structures of the wild-type gp41 core and the
G572A and R579A mutants can be superimposed, with rms
deviations of 0.39 and 0.40 Å, respectively. From the structures
we can see that each substituted alanine side chain is readily
accommodated in the trimer-of-hairpins structure by using dif-
ferent sets of atoms. Our data suggest that local structural
perturbations in the gp41 core are unlikely to be a major cause
of the fusion-defective phenotype of the G572A and R579A
glycoproteins. Instead, both mutant proteins exhibit a reduc-
tion in the steady-state level of gp120 on the cell surface. In
contrast to an earlier interpretation of the G572A phenotype
(70), our results suggest that this reduction is not due to a
deficiency in gp160 cleavage but may reflect an increase in
gp120 shedding from the envelope glycoprotein complex. We
propose that alanine mutations at Gly-572 and Arg-579 affect
the association between the gp120 and gp41 subunits in the
native envelope glycoprotein. This proposal is consistent with
previous disulfide cross-linking studies that demonstrated the
physical proximity of the Thr-605 residue of the gp41 ectodo-
main and the C-terminal region of gp120 (3). Therefore, we
suggest that Gly-572 and Arg-579 are required for maintaining
the structural integrity of the native gp120-gp41 complex. The
defect in membrane fusion may reflect this instability and the
resultant reduction in gp120 on the cell surface. Further stud-
ies of the G572A and R579A mutant glycoproteins may open
new perspectives in the search for effective approaches to sta-
bilizing the native envelope glycoprotein complex for vaccine
development.
Several approaches towards antiviral intervention have re-
cently converged to highlight the critical importance of
transiently exposed conformations of the HIV-1 envelope glyco-
protein. Synthetic peptides targeting the prehairpin interme-
diate of gp41 are now in clinical study (42). Small-molecule
inhibitors of the formation of the trimer-of-hairpins structure
have also been developed (22, 25, 66). Mutations in the enve-
lope glycoprotein that specifically arrest the fusion process at
critical steps may allow the accumulation of intermediates for
vaccine development. Further analysis of protein structure and
conformation will also provide insights into the complex biol-
ogy of HIV-1 entry.
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